KN046, a Bispecific Antibody against PD-L1 and CTLA-4, Plus Chemotherapy as First-Line Treatment for Metastatic NSCLC: A Multicenter Phase II Trial

In this multicenter phase II trial, patients with nonsquamous (non-sq) NSCLC receive pemetrexed, whereas those with sq-NSCLC receive paclitaxel, plus KN046 and carboplatin. Following four cycles, maintenance therapy included KN046 with pemetrexed for non-sq-NSCLC and KN046 for sq-NSCLC.